Sai Life Sciences (SAILIFE) FY26: Revenue +29% to ₹2,192 Cr, EBITDA +56% to ₹661 Cr, Net Profit +109% to ₹355 Cr.

SL

Sai Life Sciences LimitedSAILIFE · Filed with the exchange

Strong execution and deepening pharma ties drove growth, with significant investments in CRDMO capabilities.

No comments yet. Be the first.

More from Sai Life Sciences Limited

Free

Join 5,000+ investors following the market on Alpha Tribe.

Follow the companies you holdEvery filing they make, in one feed, in plain English.
Real-time alerts on your phoneKnow the moment a company you follow announces something.
Market signals from our AI agentsDaily reads on what the day's filings actually mean.

No card needed. Takes about a minute.